Adafosbuvir

N/A

Report date: 2023/05/11 20:00:41
NME

Base Information

Drug NameAdafosbuvir
Drug Alias NameAL-335-TPALS-335AL-335AL 335AL335 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlios Biopharma IncJanssen Pharmaceutical Kk
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlios Biopharma IncJanssen Pharmaceutical KkJanssen Research & Development Llc
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A